Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Narcolepsy - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2017, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape. Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 3, 2, 5, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively. Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Narcolepsy - Overview 6 Narcolepsy - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 12 Narcolepsy - Therapeutics Assessment 13 Assessment by Target 13 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Narcolepsy - Companies Involved in Therapeutics Development 21 Avadel Pharmaceuticals Plc 21 Bioprojet SCR 21 Evotec AG 21 F. Hoffmann-La Roche Ltd 22 H.A.C. Pharma 22 Heptares Therapeutics Ltd 23 Jazz Pharmaceuticals Plc 23 Ono Pharmaceutical Co Ltd 24 OptiNose US Inc 24 Reset Therapeutics Inc 25 Sanofi 25 SK Biopharmaceuticals Co Ltd 25 Taisho Pharmaceutical Holdings Co Ltd 26 Theranexus SAS 26 Narcolepsy - Drug Profiles 28 (flecainide acetate + modafinil) - Drug Profile 28 arbaclofen - Drug Profile 30 JZP-258 - Drug Profile 31 JZP-386 - Drug Profile 32 JZP-507 - Drug Profile 33 LGD-3437 - Drug Profile 34 mazindol - Drug Profile 35 mazindol CR - Drug Profile 36 ONO-4127 - Drug Profile 38 OPN-021 - Drug Profile 39 pentylenetetrazol - Drug Profile 40 pitolisant - Drug Profile 41 RO-5256390 - Drug Profile 44 SAR-110068 - Drug Profile 45 SKL-N05 - Drug Profile 46 Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile 52 Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile 53 Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile 54 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 55 sodium oxybate - Drug Profile 56 sodium oxybate ER - Drug Profile 59 TS-091 - Drug Profile 61 YNT-185 - Drug Profile 62 Narcolepsy - Dormant Projects 63 Narcolepsy - Discontinued Products 64 Narcolepsy - Product Development Milestones 65 Featured News & Press Releases 65 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Number of Products under Development for Narcolepsy, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H2 2017 Narcolepsy - Pipeline by Bioprojet SCR, H2 2017 Narcolepsy - Pipeline by Evotec AG, H2 2017 Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Narcolepsy - Pipeline by H.A.C. Pharma, H2 2017 Narcolepsy - Pipeline by Heptares Therapeutics Ltd, H2 2017 Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H2 2017 Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 Narcolepsy - Pipeline by OptiNose US Inc, H2 2017 Narcolepsy - Pipeline by Reset Therapeutics Inc, H2 2017 Narcolepsy - Pipeline by Sanofi, H2 2017 Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017 Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017 Narcolepsy - Pipeline by Theranexus SAS, H2 2017 Narcolepsy - Dormant Projects, H2 2017 Narcolepsy - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.